154 related articles for article (PubMed ID: 37005193)
1. Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression.
Dormegny-Jeanjean LC; Mainberger OAE; de Crespin de Billy C; Obrecht A; Danila V; Erb A; Arcay HM; Weibel S; Blanc F; Meyer G; Tomsa M; Bertschy G; Duval F; Foucher JR
Encephale; 2024 Apr; 50(2):137-142. PubMed ID: 37005193
[TBL] [Abstract][Full Text] [Related]
2. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.
Ketter TA; Post RM; Parekh PI; Worthington K
J Clin Psychiatry; 1995 Oct; 56(10):471-5. PubMed ID: 7559374
[TBL] [Abstract][Full Text] [Related]
3. Relative Effectiveness of Monoamine Oxidase Inhibitor and Tricyclic Antidepressant Combination Therapy for Treatment-Resistant Depression.
Amsterdam JD; Kim TT
J Clin Psychopharmacol; 2019; 39(6):649-652. PubMed ID: 31688401
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: An exploratory case cohort study.
Kim TT; Amsterdam JD
Acta Psychiatr Scand; 2023 Feb; 147(2):198-204. PubMed ID: 36331516
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
Tundo A; de Filippis R; Proietti L
World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
[TBL] [Abstract][Full Text] [Related]
7. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Caslake R; Macleod A; Ives N; Stowe R; Counsell C
Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase inhibitors in bipolar endogenous depressives.
Quitkin FM; McGrath P; Liebowitz MR; Stewart J; Howard A
J Clin Psychopharmacol; 1981 Mar; 1(2):70-4. PubMed ID: 7028797
[TBL] [Abstract][Full Text] [Related]
9. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults.
Shulman KI; Fischer HD; Herrmann N; Huo CY; Anderson GM; Rochon PA
J Clin Psychiatry; 2009 Dec; 70(12):1681-6. PubMed ID: 19852903
[TBL] [Abstract][Full Text] [Related]
10. The use of monoamine oxidase inhibitors in primary care.
Culpepper L
J Clin Psychiatry; 2012; 73 Suppl 1():37-41. PubMed ID: 22951241
[TBL] [Abstract][Full Text] [Related]
11. Two cases of hypomania following the addition of L-tryptophan to a monoamine oxidase inhibitor.
Goff DC
Am J Psychiatry; 1985 Dec; 142(12):1487-8. PubMed ID: 4073318
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
13. Potential efficacy of dopaminergic antidepressants in treatment resistant anergic-anhedonic depression results of the chronic anergic-anhedonic depression open trial - CADOT.
Dormegny-Jeanjean LC; de Billy C; Mainberger O; Weibel S; Schorr B; Obrecht A; Landré L; Berna F; Causin JB; Blanc F; Danila V; Tomsa M; Pfleger G; Meyer C; Humbert I; Javelot H; Meyer G; Bertschy G; Foucher JR
Front Psychiatry; 2023; 14():1194090. PubMed ID: 37829759
[TBL] [Abstract][Full Text] [Related]
14. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression.
Fawcett J; Kravitz HM; Zajecka JM; Schaff MR
J Clin Psychopharmacol; 1991 Apr; 11(2):127-32. PubMed ID: 2056139
[TBL] [Abstract][Full Text] [Related]
15. Revisiting monoamine oxidase inhibitors.
Krishnan KR
J Clin Psychiatry; 2007; 68 Suppl 8():35-41. PubMed ID: 17640156
[TBL] [Abstract][Full Text] [Related]
16. Monoamine oxidase inhibitors: safety and efficacy issues.
Brown CS; Bryant SG
Drug Intell Clin Pharm; 1988 Mar; 22(3):232-5. PubMed ID: 3284731
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of atypical antipsychotics in depressive syndromes].
Quintin P; Thomas P
Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
[TBL] [Abstract][Full Text] [Related]
18. Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells.
Mercuri NB; Scarponi M; Bonci A; Siniscalchi A; Bernardi G
J Neurosci; 1997 Apr; 17(7):2267-72. PubMed ID: 9065488
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole and Selegiline Combination Therapy in a Case of Treatment-Resistant Depression.
Moirand R; Galvao F; Dondé C
J Clin Psychopharmacol; 2019; 39(6):684-685. PubMed ID: 31688405
[No Abstract] [Full Text] [Related]
20. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
